RU2494758C2 - Neisseria vaccine compositions containing antigen combination - Google Patents

Neisseria vaccine compositions containing antigen combination Download PDF

Info

Publication number
RU2494758C2
RU2494758C2 RU2007127448/15A RU2007127448A RU2494758C2 RU 2494758 C2 RU2494758 C2 RU 2494758C2 RU 2007127448/15 A RU2007127448/15 A RU 2007127448/15A RU 2007127448 A RU2007127448 A RU 2007127448A RU 2494758 C2 RU2494758 C2 RU 2494758C2
Authority
RU
Russia
Prior art keywords
immunogenic composition
composition according
antigen
outer membrane
neisserial
Prior art date
Application number
RU2007127448/15A
Other languages
Russian (ru)
Other versions
RU2007127448A (en
Inventor
Франсуа-Ксавье Жак БЕРТЕ
Ральф БИМАН
Филипп Деноэль
Кристиан ФЕРОН
Карин ГОРАЖ
Ян Пулман
Винсент ВЕЙНАНТС
Original Assignee
ГлаксоСмитКлайн Байолоджикалз с.а.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218035A external-priority patent/GB0218035D0/en
Priority claimed from GB0218036A external-priority patent/GB0218036D0/en
Priority claimed from GB0218051A external-priority patent/GB0218051D0/en
Priority claimed from GB0218037A external-priority patent/GB0218037D0/en
Priority claimed from GBGB0220199.4A external-priority patent/GB0220199D0/en
Priority claimed from GBGB0220197.8A external-priority patent/GB0220197D0/en
Priority claimed from GB0225531A external-priority patent/GB0225531D0/en
Priority claimed from GB0225524A external-priority patent/GB0225524D0/en
Priority claimed from GB0230164A external-priority patent/GB0230164D0/en
Priority claimed from GB0230170A external-priority patent/GB0230170D0/en
Priority claimed from GB0230168A external-priority patent/GB0230168D0/en
Priority claimed from GB0305028A external-priority patent/GB0305028D0/en
Application filed by ГлаксоСмитКлайн Байолоджикалз с.а. filed Critical ГлаксоСмитКлайн Байолоджикалз с.а.
Publication of RU2007127448A publication Critical patent/RU2007127448A/en
Publication of RU2494758C2 publication Critical patent/RU2494758C2/en
Application granted granted Critical

Links

Images

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

FIELD: medicine, pharmaceutics.
SUBSTANCE: given invention refers to medicine, biopharmaceutics, and may be used to prepare vaccines. For this purpose, the immunogenic composition contains: 1) an antigen Neisseria autotransporter protein representing NadA or Hsf; 2) an antigen Neisseria protein involved in iron absorption and representing Lipo28 or low-molecular or high-molecular TbpA; and 3) a vesicle preparation of an outer membrane containing immunotype L3 Neisseria lipopolysaccharide (LPS); and wherein the above antigens if present in the outer membrane vesicle are positively regulated in accordance with recombinant technology in the above outer membrane vesicle.
EFFECT: using the given vaccine that is a combination of the various class Neisseria antigens generates the immune response which occurs to be stronger if expressed in bactericidal units.
17 cl, 11 dwg, 21 ex

Description

Текст описания приведен в факсимильном виде.

Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
The text of the description is given in facsimile form.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105

Claims (17)

1. Иммуногенная композиция, содержащая:
1) антиген нейссериальный аутотранспортерный белок, представляющий собой NadA или Hsf;
2) антиген нейссериальный белок, участвующий в усвоении железа, представляющий собой Lipo28 или низкомолекулярный и высокомолекулярный TbpA; и
3) препарат везикул наружной мембраны, включающую нейссериальный липополисахарид (LPS) иммунотипа L3;
и где указанные антигены, в тех случаях когда они присутствуют в везикуле наружной мембраны, позитивно отрегулированы рекомбинантным образом в указанной везикуле наружной мембраны.1. An immunogenic composition comprising:
1) antigen is a neisserial autotransporter protein, which is NadA or Hsf;
2) antigen is a neisserial protein involved in the absorption of iron, which is Lipo28 or low molecular weight and high molecular weight TbpA; and
3) the preparation of the outer membrane vesicles, including the neisserial lipopolysaccharide (LPS) of the L3 immunotype;
and where the indicated antigens, in those cases when they are present in the vesicle of the outer membrane, are positively recombinantly adjusted in the specified vesicle of the outer membrane. 2. Иммуногенная композиция по п.1, где антиген нейссериальный аутотранспортерный белок и антиген нейссериальный белок, участвующий в усвоении железа, являются выделенными.2. The immunogenic composition according to claim 1, where the antigen is a neisserial autotransporter protein and the antigen is a neisserial protein involved in the absorption of iron, are isolated. 3. Иммуногенная композиция по п.1, которая включает как субъединичную композицию, так и препарат везикул наружной мембраны.3. The immunogenic composition according to claim 1, which includes both a subunit composition and an outer membrane vesicle preparation. 4. Иммуногенпая композиция по п.1, где препарат везикул наружной мембраны содержит LPS иммунотипа L3, 7, 9.4. The immunogen composition according to claim 1, where the preparation of the outer membrane vesicles contains LPS immunotype L3, 7, 9. 5. Иммуногенная композиция по п.1, где препарат везикул наружной мембраны содержит LPS иммунотипа L3, которую можно получить экстракцией везикул наружной мембраны с использованием дезоксихолата в концентрации 0,02-0,4%.5. The immunogenic composition according to claim 1, where the preparation of the outer membrane vesicles contains LPS of the L3 immunotype, which can be obtained by extraction of the outer membrane vesicles with deoxycholate at a concentration of 0.02-0.4%. 6. Иммуногенная композиция по п.1, где по меньшей мере один из нейссериальных антигенов имеет происхождение из Neisseria meningitidis.6. The immunogenic composition according to claim 1, where at least one of the neusserial antigens is derived from Neisseria meningitidis. 7. Иммуногенная композиция по п.6, где все нейссериальные антигены имеют происхождение из Neisseria meningitidis.7. The immunogenic composition according to claim 6, where all the neusserial antigens are derived from Neisseria meningitidis. 8. Иммуногенная композиция по п.1, дополнительно содержащая один или более чем один бактериальный капсульный полисахарид или олигосахарид.8. The immunogenic composition according to claim 1, additionally containing one or more bacterial capsular polysaccharide or oligosaccharide. 9. Иммуногенная композиция по п.8, где бактериальные капсульные полисахариды или олигосахариды происходят из бактерий, выбранных из группы, состоящей из: Neisseria meningitidis серологической группы А, С, Y и W-135.9. The immunogenic composition of claim 8, where the bacterial capsular polysaccharides or oligosaccharides come from bacteria selected from the group consisting of: Neisseria meningitidis serological group A, C, Y and W-135. 10. Иммуногенная композиция по п.1, дополнительно содержащая адъювант.10. The immunogenic composition according to claim 1, additionally containing an adjuvant. 11. Иммуногенная композиция по п.10, где адъювант содержит соль алюминия.11. The immunogenic composition of claim 10, where the adjuvant contains an aluminum salt. 12. Иммуногенная композиция по п.11, где соль алюминия представляет собой гель гидроксида алюминия.12. The immunogenic composition of claim 11, wherein the aluminum salt is an aluminum hydroxide gel. 13. Иммуногенная композиция по п.1, где антиген нейссериальный аутотранспортерный белок представляет собой NadA.13. The immunogenic composition according to claim 1, where the antigen neisserial autotransporter protein is a NadA. 14. Иммуногенная композиция по п.1, где антиген нейссериальный белок, участвующий в усвоении железа, представляет собой Lipo28.14. The immunogenic composition according to claim 1, where the antigen is a neisserial protein involved in the absorption of iron, is Lipo28. 15. Иммуногенная композиция по п.1, содержащая дополнительный антиген, представляющий собой нейссериальный белок, ассоциированный с мембраной.15. The immunogenic composition according to claim 1, containing an additional antigen, which is a neisserial protein associated with the membrane. 16. Иммуногенная композиция по п.1, содержащая дополнительный антиген, выбранный из группы, состоящей из: GNA1870, Hap, LbpB и Omp85.16. The immunogenic composition according to claim 1, containing an additional antigen selected from the group consisting of: GNA1870, Hap, LbpB and Omp85. 17. Иммуногенная композиция по п.15 или 16, где дополнительный антиген является выделенным. 17. The immunogenic composition of claim 15 or 16, wherein the additional antigen is isolated.
RU2007127448/15A 2002-08-02 2003-07-31 Neisseria vaccine compositions containing antigen combination RU2494758C2 (en)

Applications Claiming Priority (24)

Application Number Priority Date Filing Date Title
GB0218051.1 2002-08-02
GB0218037.0 2002-08-02
GB0218035A GB0218035D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218035.4 2002-08-02
GB0218037A GB0218037D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218051A GB0218051D0 (en) 2002-08-02 2002-08-02 Vaccine composition
GB0218036.2 2002-08-02
GB0218036A GB0218036D0 (en) 2002-08-02 2002-08-02 Vaccine
GB0220199.4 2002-08-30
GB0220197.8 2002-08-30
GBGB0220199.4A GB0220199D0 (en) 2002-08-30 2002-08-30 Mutant protein and refolding method
GBGB0220197.8A GB0220197D0 (en) 2002-08-30 2002-08-30 Refolding method
GB0225524.8 2002-11-01
GB0225531A GB0225531D0 (en) 2002-11-01 2002-11-01 Vaccine
GB0225524A GB0225524D0 (en) 2002-11-01 2002-11-01 Vaccine composition
GB0225531.3 2002-11-01
GB0230170.3 2002-12-24
GB0230168.7 2002-12-24
GB0230164A GB0230164D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0230170A GB0230170D0 (en) 2002-12-24 2002-12-24 Vaccine
GB0230164.6 2002-12-24
GB0230168A GB0230168D0 (en) 2002-12-24 2002-12-24 Vaccine composition
GB0305028.3 2003-03-05
GB0305028A GB0305028D0 (en) 2003-03-05 2003-03-05 Vaccine

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2005101322/15A Division RU2317106C2 (en) 2002-08-02 2003-07-31 Neusserial vaccine compositions containing combination of antigens

Publications (2)

Publication Number Publication Date
RU2007127448A RU2007127448A (en) 2009-04-27
RU2494758C2 true RU2494758C2 (en) 2013-10-10

Family

ID=35847713

Family Applications (4)

Application Number Title Priority Date Filing Date
RU2007127448/15A RU2494758C2 (en) 2002-08-02 2003-07-31 Neisseria vaccine compositions containing antigen combination
RU2005101322/15A RU2317106C2 (en) 2002-08-02 2003-07-31 Neusserial vaccine compositions containing combination of antigens
RU2005102396/13A RU2364418C2 (en) 2002-08-02 2003-07-31 VACCINE COMPOSITIONS CONTAINING L2 AND/OR L3 IMMUNOTYPE LIPOPOLYSACCHARIDES AND ORIGINATED FROM STRAIN NEISSERIA MENINGITIDIS IgtB-
RU2005102587/15A RU2359696C2 (en) 2002-08-02 2003-07-31 Vaccine composition containing transferrin-binding protein and hsf from gram-negative bacteria

Family Applications After (3)

Application Number Title Priority Date Filing Date
RU2005101322/15A RU2317106C2 (en) 2002-08-02 2003-07-31 Neusserial vaccine compositions containing combination of antigens
RU2005102396/13A RU2364418C2 (en) 2002-08-02 2003-07-31 VACCINE COMPOSITIONS CONTAINING L2 AND/OR L3 IMMUNOTYPE LIPOPOLYSACCHARIDES AND ORIGINATED FROM STRAIN NEISSERIA MENINGITIDIS IgtB-
RU2005102587/15A RU2359696C2 (en) 2002-08-02 2003-07-31 Vaccine composition containing transferrin-binding protein and hsf from gram-negative bacteria

Country Status (1)

Country Link
RU (4) RU2494758C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2662970C2 (en) * 2012-09-18 2018-07-31 Новартис Аг Outer membrane vesicles

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055873A2 (en) * 1998-04-24 1999-11-04 Smithkline Beecham Biologicals S.A. Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
WO2001009350A2 (en) * 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2001022994A2 (en) * 1999-09-30 2001-04-05 Isis Innovation Limited Vaccines against neisseria infection
WO2001052885A1 (en) * 2000-01-17 2001-07-26 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999055873A2 (en) * 1998-04-24 1999-11-04 Smithkline Beecham Biologicals S.A. Basb006 polynucleotide(s) and polypeptides from neisseria meningitis
WO2001009350A2 (en) * 1999-08-03 2001-02-08 Smithkline Beecham Biologicals S.A. Genetically engineered bleb vaccine
WO2001022994A2 (en) * 1999-09-30 2001-04-05 Isis Innovation Limited Vaccines against neisseria infection
WO2001052885A1 (en) * 2000-01-17 2001-07-26 Chiron Spa Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins

Also Published As

Publication number Publication date
RU2364418C2 (en) 2009-08-20
RU2005102587A (en) 2005-09-10
RU2005102396A (en) 2005-10-27
RU2317106C2 (en) 2008-02-20
RU2007127448A (en) 2009-04-27
RU2005101322A (en) 2005-11-20
RU2359696C2 (en) 2009-06-27

Similar Documents

Publication Publication Date Title
JP4740738B2 (en) vaccine
RU2010119947A (en) Compositions of Meningococcal Vaccines
JP2011051997A5 (en)
BR0310062A (en) Mucosal vaccines with chitosan adjuvant and / or meningococcal antigens
EP2270172B1 (en) Combination neisserial compositions
JP2011500662A5 (en)
JP5074644B2 (en) Combination meningococcal B / C vaccine
RU2010153658A (en) MULTIVALENT VACCINE FROM NATIVE VESICULES OF THE EXTERNAL MEMBRANE OF THE MENINGOCOCCUS, WAYS OF ITS OBTAINING AND APPLICATION
EA023470B1 (en) Novel formulations which stabilize immunogenic compositions and inhibit precipitation thereof
BRPI0107679B8 (en) composition comprising Neisseria meningitidis serum group b outer membrane vesicles and an inorganic component and use thereof
TW200817034A (en) Vaccine
NO20082472L (en) Vaccine compositions comprising a saponin adjuvant
EP0789587A1 (en) Combined meningitis vaccine
BR9611218A (en) Pharmaceutical product vaccine composition processes to immunize a host against infection and to enhance an immune response
RU2494758C2 (en) Neisseria vaccine compositions containing antigen combination
Bonvehí et al. Three doses of an experimental detoxified L3-derived lipooligosaccharide meningococcal vaccine offer good safety but low immunogenicity in healthy young adults
EP1741443A2 (en) Combination meningitidis B/C vaccines
JP5676452B2 (en) Vaccine adjuvant
NO855169L (en) OIL ADJUSTED VACCINE, AND PROCEDURE FOR ITS MANUFACTURING.
BRPI0418332A (en) vaccine adjuvants, vaccine formulation, use of vaccine formulation and immunization schedule
Borrow et al. The future of meningococcal vaccines
Logesh et al. COMPARISON OF EFFICACY OF VACCINES BETWEEN MINERAL OIL AND ALUMINIUM HYDROXIDE ADJUVANT VACCINE AGAINST MYCOPLASMA GALLISEPTICUM INFECTION IN LAYER CHICKEN
CR20220132A (en) Immunogenic compositions against enteric diseases and methods for its preparation thereof
MXPA00011664A (en) Combination meningitidis b/c vaccines
Claassen et al. Production, characterization and control of a Neisseria mellillgitidis hexavalent class 1 outer membrane protein containing vesicle vaccine

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20160801